Story perspectives
J&J's New Lung Cancer Treatments Show Promising Survival Rates
1/8/2025
50 8
1 of 1
Story summary
- Johnson & Johnson's lung cancer treatment, Rybrevant and Lazcluze, shows over a year of improved survival compared to AstraZeneca's Tagrisso.
- Results from a pivotal trial are set for presentation later this year.
- J&J targets Tagrisso's market, which currently has a median survival of three years.
- There are concerns regarding side effects and infusion requirements of J&J's treatment.
- J&J anticipates annual sales could surpass $5 billion.
